Tremelimumab Plus Durvalumab and Chemotherapy in Advanced Non–Small Cell Lung Cancer

home / approval-alert / tremelimumab-plus-durvalumab-and-chemotherapy-in-advanced-non-small-cell-lung-cancer

Tremelimumab Plus Durvalumab and Chemotherapy in Advanced Non–Small Cell Lung Cancer

In November 2022, the FDA approved tremelimumab plus durvalumab and platinum-based chemotherapy for patients with metastatic non–small cell lung cancer who have an EGFR mutation or ALK alteration.

Articles
FDA Approves Tremelimumab Plus Durvalumab for Advanced NSCLC

FDA Approves Tremelimumab Plus Durvalumab for Advanced NSCLC

November 10th 2022

The FDA has approved tremelimumab plus durvalumab for patients with metastatic non–small cell lung cancer based on findings from arms 1 and 3 of the phase 3 POSEIDON trial.

Videos
Melissa L. Johnson, MD, on the Approval of Tremelimumab Plus Durvalumab/Chemo in NSCLC

Melissa L. Johnson, MD, on the Approval of Tremelimumab Plus Durvalumab/Chemo in NSCLC

November 17th 2022

Melissa L. Johnson, MD, spoke about the design of the phase 3 POSEIDON trial how its data led to the recent approval of tremelimumab plus durvalumab and chemotherapy in patients with advanced non–small cell lung cancer.